Explore articles tagged with #HariKiranChereddi
HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.
HRV Pharma is expanding across two layers of the pharmaceutical value chain through its acquisition of Phatebo GmbH. The combination brings together HRV's global API partner network and Phatebo's licensed European clinical trial supply and pharmaceutical distribution capabilities, while retaining the asset-light business model.
HRV Pharma has expanded beyond APIs into clinical trial supply through its acquisition of Germany-based Phatebo. The company sources comparator, investigational and ancillary medicines for pharmaceutical companies and CROs worldwide, bringing HRV into a segment where reliability, traceability and timely delivery are essential.
HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.
HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
Hari Kiran Chereddi, Founder, MD & CEO, HRV Pharma, explores how asset-light manufacturing can help pharmaceutical companies build greater flexibility, scalability and efficiency into their manufacturing strategies.
HRV Pharma Founder, MD & CEO Hari Kiran Chereddi shares insights in Express Pharma on India’s opportunity to become a strategic global CDMO partner through specialised capabilities, regulatory strength, scientific expertise and reliable execution.
HRV Pharma is investing around ₹150 crore in peptides and high-potency oncology APIs, expanding specialised manufacturing capabilities through an asset-light model and strategic manufacturing partnerships.
CEO Hari Kiran and CIO Sowjanya Varma in Express Pharma on why pharma’s next advantage lies in reasoning rather than more systems - and how RIKO™ shifts compliance from retrospective to predictive.
HRV Pharma and Haleos Labs have entered into a multi-year strategic partnership to accelerate the development and GMP manufacturing of specialty APIs for regulated and semi-regulated markets.
India’s proposed amendments to the Drugs Rules, 1945 could require pharmaceutical companies to clearly distinguish biological medicines from synthetic drugs, with implications for classification, traceability, quality and regulatory oversight.
Digital transformation is reshaping pharmaceutical manufacturing in India, with technologies such as MES, electronic batch records, LIMS, digital twins, predictive analytics and AI helping strengthen compliance, data integrity and operational efficiency.
The API industry is rethinking how manufacturing capacity and supply chains are structured, with manufacturing networks offering a more resilient approach through qualified partners, regulatory ownership and greater visibility.
The pharmaceutical industry's competitive edge is evolving from manufacturing capacity to institutional intelligence. Indian Pharma Post explores how HRV Pharma's RIKO uses seven years of proprietary operational data to assess risks, accelerate supplier qualification and support smarter pharmaceutical decision-making.
Why do preventable pharmaceutical problems keep recurring years after key decisions are made? Digital Health News explores how HRV Pharma's RIKO uses seven years of operational workflows and ten federated reasoning models to identify risks earlier, accelerate supplier qualification and support faster pharmaceutical decision-making.
HRV Pharma's RIKO is designed to bridge the gap between pharmaceutical manufacturers and customers. Drawing on millions of proprietary decisions across 55 countries, the AI-native platform supports faster partner qualification, transparent enquiry matching and early risk assessment across the pharmaceutical value chain.
In the pharmaceutical industry, identifying risks early can help prevent costly quality failures and recalls. PharmaClick explores how HRV Pharma's RIKO platform uses AI-driven pharmaceutical intelligence to assess chemistry risks, nitrosamine potential, supplier reliability and regulatory history before commitments are made.
Millennium Newsroom highlights the reported results of RIKO, HRV Pharma's AI-native pharmaceutical operating system. From 94% predictive accuracy in early nitrosamine risk assessments to 85% faster supplier qualification and commercial enquiry screening in under two seconds, RIKO applies pharmaceutical decision intelligence to real business challenges.
HRV Pharma has launched RIKO, an AI-native pharmaceutical operating system built on more than seven years of industry decisions. Drawing on insights from a network of 50+ FDA and EU GMP certified partners and customers across 55 countries, RIKO brings together AI-driven reasoning to support pharmaceutical sourcing, risk assessment and supplier qualification.
RIKO™ is a self-learning reasoning engine built on seven years of proprietary pharmaceutical decisions across 50+ GMP-certified partners in 55 countries.
How can a pharmaceutical company maintain quality without owning its manufacturing plants? HRV Pharma builds trust through standardised audits, real-time performance tracking and continuous visibility across 53 partners, helping identify issues before they become shipment or regulatory problems.
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
Business Standard explores HRV Pharma’s asset-light model, which combines regulatory assets, drug master files and customer relationships with a network of 53 manufacturing partners to build pharmaceutical scale without owning manufacturing facilities.
HRV Pharma is redefining pharma economics by turning regulatory filings (DMFs) into scalable global assets—shifting value from manufacturing to compliance and market access.
HRV Pharma CEO Hari Kiran Chereddi explains why drug development success is now determined before manufacturing, driven by data, predictive analytics, and strategic decision-making.
HRV Pharma CEO Hari Kiran Chereddi shares insights on how platform-driven models are transforming pharma from factory-led systems to intelligent, network-based ecosystems.
HRV Pharma partners with Shodhana Laboratories to accelerate next-generation API development, combining AI-enabled virtual manufacturing with precision chemistry and global regulatory execution.
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
India's rise in biosimilars & biologics. Full clipping + insights included.